Personalized treatment for selected patients with cancer target
- To overcome the limitations of existing anticancer drugs, the company is developing biomarker-based personalized medicines. These are drugs targeting specific markers within the 'cancer microenvironment' for colorectal cancer, and it has been confirmed that these are expressed in most colorectal cancer tissues.
- In the future, the company plans to continue to discover new targets derived from the tissues and clinical information of various patients with solid cancer, and to establish a drug development strategy necessary for specific patients.
Current Medicine Standardized threrapy
Future Medicine Personalized therapy
Personalized New Drugs based on Biomarkers
-
Personalized treatment by biomarkers
Select anti-cancer drugs according to biomark- ers regardless of the primary cancer type
Prediction of treatment response by biomarker diagnosis
-
Targeted Therapy by various mechanism
Suppression of cancer growth and metastasis through regulation of cancer and tumor microenvironment
Overcoming the Limitations of Conventional Anticancer DrugsControl the interaction between cancer and the microenvironment
-
Combination therapy inducing immune response
Regulation of immunosuppression in tumor microenvironment
Increases the efficiency of immunotherapyCombination therapy
Biomarkers and new drug targets developed during the medical device development stage Extending to Antibody Therapeutics
Discovery of cancer- specific biomarkers
- Imaging and quantification of in vivo molecular targets
- Early diagnosis of precancerous lesions
- Identification of tumor histopathology
- Prediction of chemotherapeutic response in cancer
